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Leucine-rich repeat kinase 2 (LRRK2) is a complex, multidomain protein which is
considered a valuable target for potential disease-modifying therapeutic strategies for
Parkinson’s disease (PD). In mammalian cells and brain, LRRK2 is phosphorylated
and treatment of cells with inhibitors of LRRK2 kinase activity can induce LRRK2
dephosphorylation at a cluster of serines including Ser910/935/955/973. It has
been suggested that phosphorylation levels at these sites reflect LRRK2 kinase
activity, however kinase-dead variants of LRRK2 or kinase activating variants do not
display altered Ser935 phosphorylation levels compared to wild type. Furthermore,
Ser910/935/955/973 are not autophosphorylation sites, therefore, it is unclear if inhibitor
induced dephosphorylation depends on the activity of compounds on LRRK2 or on yet
to be identified upstream kinases. Here we used a panel of 160 ATP competitive and
cell permeable kinase inhibitors directed against all branches of the kinome and tested
their activity on LRRK2 in vitro using a peptide-substrate-based kinase assay. In neuronal
SH-SY5Y cells overexpressing LRRK2 we used compound-induced dephosphorylation of
Ser935 as readout. In silico docking of selected compounds was performed using a
modeled LRRK2 kinase structure. Receiver operating characteristic plots demonstrated
that the obtained docking scores to the LRRK2 ATP binding site correlated with in vitro
and cellular compound activity. We also found that in vitro potency showed a high degree
of correlation to cellular compound induced LRRK2 dephosphorylation activity across
multiple compound classes. Therefore, acute LRRK2 dephosphorylation at Ser935 in
inhibitor treated cells involves a strong component of inhibitor activity on LRRK2 itself,
without excluding a role for upstream kinases. Understanding the regulation of LRRK2
phosphorylation by kinase inhibitors aids our understanding of LRRK2 signaling and may
lead to development of new classes of LRRK2 kinase inhibitors.
Keywords: docking, MOE, LRRKtide, Parkinson’s disease, kinase, phosphorylation, inhibitor, receiver operator
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INTRODUCTION
Leucine-rich repeat kinase 2 (LRRK2) is a 2527 amino-acid long
complex multidomain protein which is a member of the ROCO
protein family. This family of proteins is derived from a signature
homologous region including a domain encoding for a GTPase
of the Ras family, termed ROC (for Ras of complex proteins)
(Taymans, 2012), followed by a characteristic COR (C-terminal of
ROC) domain. The ROC-COR bidomain is flanked C-terminally
by a kinase domain and a WD40 domain and N-terminally by an
armadillo repeat domain (ARM), ankyrin repeat domain (ANK),
and the namesake leucine-rich repeat (LRR) domain. LRRK2 has
primarily been studied for its role in Parkinson’s disease (PD)
(Cookson, 2010), but is also reported to play a role in cancer,
Crohn’s disease, and leprosy (Lewis and Manzoni, 2012). LRRK2
is the single most prevalent genetic cause of PD known to date
(Paisan-Ruiz et al., 2008). Together with alpha-synuclein, LRRK2
has been both linked to familial PD and associated to sporadic
PD (Singleton et al., 2013). Also, PD patients carrying the LRRK2
mutations show a clinical and neuropathological profile which
is indistinguishable from sporadic PD, indicating that LRRK2
may contribute to a PD pathway common to both familial and
sporadic PD (Healy et al., 2008).
The kinase activity of LRRK2 has been proposed as a promis-
ing target for developing disease modifying therapy for PD
(Greggio and Singleton, 2007; Vancraenenbroeck et al., 2011; Lee
et al., 2012) and deletion of LRRK2 kinase activity has been
shown to be protective in cellular (Greggio et al., 2006; Smith
et al., 2006) or in vivo models (Lee et al., 2010; Yao et al., 2013)
of LRRK2 mediated toxicity. Currently, several compounds have
been reported that are capable of inhibiting LRRK2 kinase activity
(reviewed previously; Vancraenenbroeck et al., 2011; Deng et al.,
2012; Kramer et al., 2012). Of these examples, staurosporine,
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K252A, and sunitinib are promiscuous kinase inhibitors, known
to bind several classes of kinases. Other described compounds are
active on specific classes of kinases such as Ro-31-8220, H1152,
and Y-27632 (Davies et al., 2000; Bain et al., 2007). Recently,
several inhibitors for LRRK2 with an in vitro potency in the
low nanomolar range have been described including LRRK2-IN1
(Deng et al., 2011), CZC-25146 (Ramsden et al., 2011), TAE684
(Zhang et al., 2012), GSK2578215A (Reith et al., 2012), or HG-
10-102-01 (Choi et al., 2012). These compounds are currently
being implemented as tool compounds in basic research stud-
ies on LRRK2 and indicate the feasibility of developing LRRK2
inhibitors for other applications such as implementation as an
imaging tracer or clinical testing.
One key question in assessing LRRK2 kinase inhibitors for
these various applications involves understanding the molecu-
lar consequences of kinase inhibition in cells. Some clues are
given recently from the effects of various inhibitors on the
phosphorylation state of LRRK2 in cells. LRRK2 is a highly
phosphorylated protein in cells with a notable cluster of phos-
phorylation sites in the interdomain region between the ANK and
LRR domains, including sites Ser910/S935/S955/S973 (West et al.,
2007; Gloeckner et al., 2010; Nichols et al., 2010; Lobbestael et al.,
2012). Interestingly, these sites are dephosphorylated in cells or
tissues following treatment by inhibitors of LRRK2 kinase activ-
ity (Dzamko et al., 2010; Choi et al., 2012; Doggett et al., 2012). It
is tempting to conclude from these studies that phosphorylation
levels at these sites reflects LRRK2 kinase activity, however kinase-
dead variants of LRRK2 (K1906M or D2017A) or kinase acti-
vating variants (G2019S, T2031S) do not display altered Ser935
phosphorylation levels compared to wild type (Nichols et al.,
2010; Lobbestael et al., 2013). Furthermore, Ser910/935/955/973
are not autophosphorylation sites but are rather sites phos-
phorylated by other kinases (West et al., 2007; Dzamko et al.,
2010; Gloeckner et al., 2010; Nichols et al., 2010; Doggett et al.,
2012), therefore, it is unclear if inhibitor induced dephospho-
rylation of LRRK2 wildtype depends on the activity of com-
pounds on LRRK2 or on yet to be identified upstream kinases.
We have recently shown that LRRK2 regulates its own dephos-
phorylation through protein phosphatase 1, including dephos-
phorylation induced by the LRRK2 kinase inhibitor LRRK2-IN1
(Lobbestael et al., 2013). It remains to be verified that LRRK2
inhibitor-induced dephosphorylation is generalized across multi-
ple chemical classes and whether dephosphorylation is correlated
to inhibitor binding to LRRK2 kinase.
In the present study, we addressed these issues using a chemi-
cal biology approach. A panel of cell permeable kinase inhibitors
targeting all branches of the kinome was tested for its activity on
LRRK2 in vitro as well as in cells. Using an optimized LRRK2
kinase homology model, selected compounds were docked in sil-
ico to assess binding at the ATP-binding site.
RESULTS
TESTING OF A KINASE INHIBITOR PANEL ON LRRK2 IN VITRO KINASE
ACTIVITY
The assay employed here is based on phosphorylation of a pep-
tide termed LRRKtide derived from the cytoskeleton-associated
moesin protein (Jaleel et al., 2007) and is adapted to a phosphor
imaging readout (Asensio and Garcia, 2003; Taymans et al., 2011),
as described in Materials and Methods and shown in Figure 1.
The quality of the chosen assay is given by the average Z′ fac-
tor for this assay which we determined to be 0.82 (Figure 2),
well within the range of 0.5–1 which is considered an excel-
lent value for screening assays (Zhang et al., 1999). A panel of
160 kinase inhibitors was tested in the LRRK2 in vitro kinase
activity assay using GST-LRRK2970-2527 at one concentration
(10μM) (Figure 1, quantifications given in Table 1). Of these 160
compounds, 35 compounds from three compound classes (A) 9-
methyl-N-phenylpurine-2,8-diamine, (B) N-phenylquinazolin-
4-amine, and (C) 1,3-dihydroindol-2-one analogs were selected
for further testing in the in vitro assay as well as for in silico
analysis (see further). These three compound classes were chosen
because they contain compounds with a common core or scaf-
fold possessing a wide variety of activities. Additionally, known
LRRK2 reference compounds were tested including LRRK2-
IN1, CZC-25146 and the pan-kinase inhibitor staurosporine as
well as compound CDK1/2 inhibitor III which displayed high-
est potency in inhibiting LRRK2. The selected compounds were
retested with full length recombinant enzyme at 100μM, 10μM,
1μM and 100 nM. For those compounds that inhibited LRRK2
kinase activity more than 50% at 1μM, a pIC50 [= −log(IC50)]
value was determined as described in Materials and Methods
(Figure 2 and Table 2). It can be noted that for known LRRK2
inhibitory compounds that we included in our testing, our
adapted LRRKtide phosphorylation assay yielded similar poten-
cies to those previously published (comparative examples of
obtained IC50 values are: LRRK2-IN1 3.54 nM vs. 13 nM (Deng
et al., 2011), CZC-25146 1.78 nM vs. 4.76 nM (Ramsden et al.,
2011), with values given from this study and from published
studies, respectively; for the LRRK2-IN1 comparison, the slightly
lower value obtained here may be due to the ATP concentrations
used which are 10μM in the present study and 100μM in the
original study).
TESTING OF KINASE INHIBITOR PANEL IN LRRK2 CELLULAR
PHOSPHORYLATION ASSAY
Using the same panel of 160 kinase inhibitors, cellular activity was
assayed by monitoring dephosphorylation of LRRK2 at Ser935
induced by kinase inhibitor treatment (5μM for 2 h) of the SH-
SY5Y cell line with stable expression of LRRK2 as described in
Materials and Methods and shown in Figure 3. The mean Z′ fac-
tor for the dual detection immune-dotblot assay used here is
0.65 (Figure 4). A total of 20 compounds were found to reduce
Ser935 phosphorylation levels to less than 50% of control levels
(Tables 1, 2), all are ATP-binding site competitive compounds.
None of the 20 non ATP-competitive compounds of the panel
(see Materials and Methods) induce more than 50% dephos-
phorylation of LRRK2 at 5μM although AG490 shows 49.32%
dephosphorylation of LRRK2 at 5μM. Representative dot blot
images and bar diagrams are depicted in Figure 3, exact quan-
tifications are given in Table 1. For the selected compounds, the
IC50 was determined (Figure 4 and Table 2).
CORRELATION BETWEEN IN VITRO AND CELLULAR ACTIVITY OF
COMPOUNDS
Correlations between the in vitro and cellular activities for each
compound were investigated by drawing up correlation plots for
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FIGURE 1 | Testing of effect of reference kinase inhibitors on in vitro
LRRK2 kinase activity. (A,B) 160 kinase inhibitors from a panel of
inhibitors known to target kinases in all branches of the kinome were
tested for their ability to inhibit LRRK2 at 10μM in an in vitro kinase
assay using the LRRKtide model peptide substrate, as described in
Materials and Methods. (A) Quantification of the LRRKtide
phosphorylation level for each kinase reaction. Signal intensity per
reaction was quantified via densitometry as described in Materials and
Methods and values are normalized to phosphorylation levels measured
in solvent controls (control values are set at 100%). Values obtained
(mean ± s.e.m., N = 3) are depicted as histogram bars ordered from
least active to most active compound, showing that the panel comprises
a broad range of activity on LRRK2 kinase function. Exact values are
given in Table 1. (B) Representative autoradiograms of P81 paper
spotted with kinase reactions from testing of the 160 compounds which
were used for densitometric quantification given in A. Also shown at the
right of the first panel are the solvent controls as well as positive
controls using potent inhibitors of the LRRK2 kinase, TAE684,
staurosporine, LRRK2-IN1, and CZC-25146. Illustration of detailed IC50
determination for active compounds is given in Figure 2.
FIGURE 2 | Dose-response curves and Z′ factor determination for in vitro
LRRKtide assay. (A,B) Detailed IC50 determinations were performed for
selected active compounds by testing LRRKtide phosphorylation in the
presence of a range of inhibitor doses, as described in Materials and
Methods. A representative autoradiogram for compound SU11652 is given
(A) as well as the fitted inhibition curves obtained for five compounds (B)
In vitro IC50 values for each tested compound are given in Table 2. (C)
LRRKtide phosphorylation values were used to calculate the Z′ of the in vitro
LRRKtide phosphorylation assay using the formula given in Materials and
Methods.
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FIGURE 3 | Testing of effect of reference kinase inhibitors on cellular
LRRK2 pS935 levels. 160 kinase inhibitors from a panel of inhibitors
known to target kinases in all branches of the kinome were tested for
their ability to dephosphorylate LRRK2 at phosphoserine 935 in a
spotblot assay, as described in Materials and Methods. (A)
Quantification of the cellular phosphorylation level at Ser935 for each
compound and ranked from least to most active (exact values per
compound can be found in Table 1). (B) Representative spot blots
detecting phospho-LRRK2 (pS935 detection in upper panels) and
total-LRRK2 (LRRK2 detection in lower panels) for 160 kinase inhibitors
tested at 5μM. Illustration of detailed IC50 determination for active
compounds is given in Figure 4.
these two parameters and performing linear regression analysis
as described in Materials and Methods (Figure 5). This analy-
sis showed a significant correlation between in vitro and cellular
activity (with Pearson’s r coefficient of −0.7953).
LRRK2 KINASE STRUCTURAL MODEL
We constructed, optimized and quality improved a 3D homol-
ogy model of the LRRK2 kinase domain as described in detail in
Materials and Methods. Based on their sequence identity with the
LRKK2 kinase domain, the tyrosine-kinase like (TKL) kinases B-
Raf (PDB 3OG7; Bollag et al., 2010),MLK1 (PDB 3DTC;Hudkins
et al., 2008), and IRAK-4 (PDB 2NRU; Wang et al., 2006) were
selected as templates to model LRRK2 kinase (see Table 3 for
an overview of TKL kinases with available 3D structures and
their sequence identity with the LRRK2 kinase domain). The
alignment between the LRRK2 kinase domain and these three
kinases is given in Figure 6A. The final homology model colored
by conserved kinase motifs is shown in Figure 6B; the final model
colored by quality of each predicted amino-acid position is given
in Figure 6C and was determined as described in the Materials
andMethods section. The ATP-binding groove lies at the interface
of the N-and C-terminal lobes (Huse and Kuriyan, 2002; Nolen
et al., 2004).
IN SILICO ANALYSIS OF LRRK2 KINASE—LIGAND INTERACTIONS
A preliminary docking step, where staurosporine was docked
in the LRRK2 ATP-binding site, was applied to optimize the
local environment to get the most optimal binding pose during
the subsequent docking step. 35 compounds from three com-
pound classes (A) 9-methyl-N-phenylpurine-2,8-diamine, (B)
Frontiers in Molecular Neuroscience www.frontiersin.org June 2014 | Volume 7 | Article 51 | 4
Vancraenenbroeck et al. Kinome-wide analysis of LRRK2 dephosphorylation
FIGURE 4 | Dose-response curves and Z′ factor determination for
Ser935 cellular dephosphorylation assay. (A) Representative spotblot
of cell lysates of SH-SY5Y stably overexpressing 3flag-LRRK2 WT and
treated with a dose range of reference compounds LRRK2-IN1 or CZC
using concentrations as indicated. DMSO treatment was included as a
control. Total LRRK2 protein was detected with Flag-M2 antibody,
phosphorylation at Ser935 with a monoclonal LRRK2 PS935 antibody. (B)
Fitting of inhibition curves based on spot intensity in (A) (determined
by densitometric analysis and used to quantify phosphorylation levels
relative to total LRRK2 levels) and IC50 determination of
phosphorylation at LRRK2 Ser935 for reference compounds LRRK2-IN1
and CZC. N ≥ 5. Cellular pS935 dephosphorylation IC50 values for each
tested compound are given in Table 2. (C) Representative spotblot of
cell lysates of SH-SY5Y stably overexpressing 3flag-LRRK2 WT and
treated with DMSO or 10μM CZC. Phosphorylation level values derived
from total LRRK2 and phospho-LRRK2 levels quantified via spotblot
were used to calculate the Z′ of the pS935 dephosphorylation assay
using the formula given in Materials and Methods.
FIGURE 5 | Correlation plot of cellular activity (pS935 spotblot assay)
and in vitro potency (pIC50 of LRRKtide assay). The assessment is
performed for compounds with in vitro pIC50 of 5 or better. Exact values of
the plotted data are given in Table 2.
N-phenylquinazolin-4-amine, and (C) 1,3-dihydroindol-2-one
analogs were docked into this active site using three class-specific
pharmacophore models (Figures 7A–C) as described in detail
in Materials and Methods. A summary of the in silico docking
scores, given as the Generalized-Born Volume Integral/Weighted
Surface area dG (GBVI/WSA dG) is given in Table 2. To eval-
uate the correlation between docking and in vitro and cellu-
lar compound activities, receiver operating characteristic plots
describing the trade-off between sensitivity and specificity were
constructed using the GVBI/WSA dG computed values and the
measured in vitro activities in the LRRKtide assay (IC50 of 1μM
or better is scored active) or the measured pS935 cellular dephos-
phorylation (a measure of greater than 50% dephosphorylation
at 5μM is scored as active). Receiver operating characteristic
plots which trace above the diagonal signify docking enrich-
ment, with best docking for those receiver operating character-
istic plots furthest above the diagonal. An indicative parameter
of the receiver operating characteristic plot is the area under
the curve (AUC) with values above 0.5 indicating a valid cor-
relation between in silico and measured activity values. The
receiver operating characteristic plots were determined for the
LRRK2 kinase model as well as the three separate kinase struc-
tures which were used as templates for constructing the LRRK2
kinase model. These receiver operating characteristic plots, dis-
played in Figures 7D–K clearly show that of these four models,
only docking results obtained with the LRRK2 kinase domain
model itself have predictive value for in vitro kinase activity and
cellular pS935 dephosphorylation activity for at least three dif-
ferent structural classes of LRRK2-active compounds. Illustrative
LRRK2 kinase—ligand binding poses for representative active
compounds representing the three different classes are given
in Figure 8.
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FIGURE 6 | Structural modeling of the LRRK2 kinase domain (residues
1859–2138). (A) Target (the LRRK2 kinase domain)—template (2NRU, 3DTC,
and 3OG7) alignment (see Table 3 for an overview of available structural
templates of TKL kinases). Secondary structure elements (predicted for
LRRK2 via NetSurfP or obtained from the 3D PDB structure) are indicated:
α-helices are red italic, and β-strands yellow underlined. The conserved
motifs are highlighted in bold and labeled. Identical residues are marked with
an asterisk (∗). (B) Illustration of the LRRK2 kinase homology model depicting
key residues and functional features. The P-loop is shown in red, the
conserved K in β3 and E in αC in green, the catalytic loop in purple, the
activation loop in yellow, the gatekeeper (gk), gk + 1, and gk +3 residues
from the hinge region in blue. Sticks colored by CPK convention correspond
to the residues that are affected by the G2019S and I2020T mutations
segregating with PD. G2019S is part of the beginning of the activation loop.
(C) Graphical representation of potential errors in the homology model as
predicted by Meta-MQAPII. The color spectrum from blue to red reflects the
accuracy of the 3D residue prediction from correct to incorrect respectively.
The spheres indicate the position of the residues in the disallowed and
generously allowed regions of the Ramachandran Plot and residues with
unfavorable bond angles and dihedrals. Figures generated with PyMol.
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FIGURE 7 | Illustration of the pharmacophore queries used during
“pharmacophore filtering” and receiver operating characteristic plots
assessing the correlation between inhibitor docking and in vitro or
cellular activity. (A–C) Pharmacophore queries are illustrated for purine,
quinazoline and oxindol derivatives [termed compound classes (A–C),
respectively, panels (A–C), respectively]. Shown are the hinge region
residues, pharmacophore features and the substructure of the respective
class. Only the main chain and Cβ side chain atoms are shown for the gk-1,
gk+1, gk+2, gk+3, and gk+4 residues. Depicted pharmacophore features
include aromatic rings (orange spheres), hydrogen bond acceptors (cyan
spheres), or donors (purple spheres). The substructures of the respective
compound classes are shown in stick representation. All molecules are
colored by CPK convention. Abbreviations: Acc, acceptor; Aro, aromatic; Don,
donor; gk, gatekeeper. Figures generated with MOE. (D–K) The receiver
operating characteristic plots were determined to evaluate the predictive
power of the docking method in the LRRK2 model compared to the separate
templates used to generate the LRRK2 model, i.e., B-Raf (3OG7), MLK1
(3DTC), and IRAK-4 (2NRU). Using the activity measures for in vitro activity
(D–G) or cellular activity (H–K), true positive rate (measure for sensitivity) as
function of false positive rate (indication of specificity) is plotted. The Area
Under Curve (AUC)-value of each receiver operating characteristic plot is
indicated on the plot, with an AUC > 0.5 indicating predictive value of the
docking. (D,H) receiver operating characteristic plots of LRRK2 docking, (E,I)
receiver operating characteristic plots of MLK1 docking, (F,J) receiver
operating characteristic plots of B-Raf docking, (G,K) receiver operating
characteristic plot of IRAK4 docking. Docking scores are given in Table 2.
DISCUSSION
The relationships between binding of kinase inhibitors to the
LRRK2 kinase pocket, in vitro inhibition of LRRK2 kinase activ-
ity and inhibitor-induced cellular dephosphorylation of LRRK2
hold clues for understanding LRRK2 signaling and interpreting
LRRK2 cellular activity assays. Here, we assessed the interrelation-
ship between these parameters, using in silico, in vitro and cellular
activity assays. Using a panel of 160 reference kinase inhibitors
targeting all branches of the kinome, we found a broad range
of potencies to inhibit LRRK2 in vitro kinase activity, ranging
from inactive compounds to compounds inhibiting LRRK2 in
the subnanomolar range. Similarly, the panel of kinase inhibitors
displayed a broad range of cellular potencies with strongest com-
pounds active in the low nanomolar range. Finally, the picture
of activities was completed by determining in silico docking of
compounds selected from three different structural classes which
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FIGURE 8 | Predicted ligand binding poses. (A–C) Selected active
compounds of the three different compound classes are depicted in the
LRRK2 kinase ATP-binding pocket. Compounds shown are (A)
Aminopurvalanol A (purine derivative), (B) JAK3 Inhibitor II (quinazoline
derivative), and (C) SU6656 (oxindole derivative). LRRK2 kinase is given in
cartoon and line representation, the ligands in stick representation. The blue
dotted lines denote hydrogen bond interactions. The green dotted lines
denote π—cation interactions. (D–F) Schematic representation of the
interactions between the LRRK2 kinase active site and the compound from
panels (A–C): (D) Aminopurvalanol A, (E) JAK3 Inhibitor II, and (F) SU6656.
See box for the explanation of colors and arrows. Figures generated with
MOE.
included compounds with identical scaffolds but varying activi-
ties ranging from potent to inactive in the in vitro kinase assay
and cellular dephosphorylation assay.
The activity assays selected and optimized here are suitable to
predict activity of compounds on LRRK2. First, for the in vitro
activity and cellular activity assays, we used established assays
with slight modifications, and we could demonstrate excellent
Z′-factors for these assays in our hands (Z′ of 0.82 for the in vitro
assay and of 0.65 for the cellular assay). The results obtained
with LRRKtide in vitro phosphorylation assay as performed
here yielded potencies similar to those reported for compounds
tested in previously published studies. Using LRRK2-IN1 as a
benchmark, the IC50 value obtained here of 3.54 nM is compara-
ble to the published value (13 nM) (Deng et al., 2011). The same
Frontiers in Molecular Neuroscience www.frontiersin.org June 2014 | Volume 7 | Article 51 | 8
Vancraenenbroeck et al. Kinome-wide analysis of LRRK2 dephosphorylation
holds true for the second assay testing cellular activity which is
based on kinase inhibitor induced dephosphorylation of LRRK2
at Ser935 and adapted here using a spotblot readout. For instance,
for LRRK2-IN1 the IC50 value obtained here (279.9 nM) is in
the same range as IC50 values obtained with other readouts
of pS935 levels such as western blot (about 100 nM; Dzamko
et al., 2010; Deng et al., 2011), time-resolved FRET (90–200 nM;
Hermanson et al., 2012), or ELISA (50–100 nM; Delbroek et al.,
2013). Thirdly, in the absence of a physical 3D atomic structure
of the LRRK2 kinase domain, an optimized 3D homology model
was generated for in silico docking. Because the available tem-
plates with closest homology showed only 30% sequence identity,
we took great care in optimizing the model. Homology models
of the LRRK2 kinase domain have been constructed before (see
for example references; Marin, 2006; Mata et al., 2006; Nichols
et al., 2009; Deng et al., 2011; Yun et al., 2011), however here
we refined the model extensively for use in molecular docking
studies. In particular, alignments between LRRK2 kinase and
potential templates were performed using alternative sequence-
to-structure alignments guided by conserved residues Also, multi-
ple templates were used to employ the most appropriate template
for each structural segment. Finally, the best model was cho-
sen according to the model evaluation rather than the alignment
score.
Our results show a strong correlation between the potency of
compounds to inhibit LRRK2 in vitro kinase activity and potency
to dephosphorylate LRRK2 in cells (Pearson’s r = −0.7953,
Figure 5). Kinase inhibitor induced dephosphorylation of LRRK2
in cells could be seen for compounds with an in vitro IC50
of 10μM or better. Conversely, the majority of the com-
pounds which were inactive in vitro (no activity at 10μM) were
also inactive in cells. This is consistent with the notion that
kinase inhibitors induce dephosphorylation through inhibition
of LRRK2 kinase activity and/or through binding to the LRRK2
kinase ATP binding pocket. This conclusion is supported by
receiver operating characteristic plots generated with the com-
pound docking scores and the in vitro potency of each tested
compound. It is often observed that in many cases docking
based virtual screening performs no better than random selec-
tion. Inclusion of pharmacophore methods however has shown
to significantly improve the virtual screening performance (Voet
et al., 2014). As such we also combine pharmacophore models in
our virtual screening setup. Via this approach, docking into our
modeled LRRK2 kinase structure is clearly better in discriminat-
ing actives from decoys than docking into the three other kinases
which were used to generate the LRRK2model. Therefore, we can
conclude that the in vitro and cellular activities of the compounds
of the three structural classes tested are likely dependent on their
binding to the LRRK2 ATP-binding site.
While it is not surprising that LRRK2 kinase activity is inhib-
ited more potently by compounds that bind more tightly to the
kinase, this is less evident for the correlation between binding
and cellular dephosphorylation of LRRK2. Indeed, kinase inhibi-
tion of LRRK2 would be expected to reduce the phosphorylation
rate of LRRK2 autophosphorylation sites (Greggio et al., 2009;
Gloeckner et al., 2010), however the Ser935 used in the assay is
not an autophosphorylation site (Nichols et al., 2010; Doggett
et al., 2012; Lobbestael et al., 2012), rather it is a site phospho-
rylated by other kinases. This has implications for the signaling
properties of LRRK2. Indeed, the direct regulation of the phos-
phorylation/dephosphorylation equilibrium in cells involves two
partners, a phosphatase and a kinase. Using the kinase inhibitor
signaling panel with broad coverage of the kinome, we expected to
identify at least a few compounds which would be inactive on the
LRRK2 kinase activity in vitro, but active in dephosphorylating
LRRK2 as these active compounds would point to the upstream
kinases of LRRK2. Looking to Table 1, only a handful of in vitro
inactive compounds (such as LY303511, DNA-PK inhibitor V,
Aurora kinase inhibitor 3, BAY11-7082) could affect moderate
dephosphorylation of LRRK2 (∼50%). These four compounds
are directed against kinases of different branches of the kinome:
LY303511 (lipid kinases branch), DNA-PK inhibitor V (atypical
kinases branch), Aurora kinase inhibitor 3 (other kinase branch),
BAY11-7082 (other kinases branch). Although these compounds
were not among the top hits of the study, further characterization
of these compounds on their effects in regulating LRRK2 phos-
phorylation may provide more information on putative upstream
kinases of LRRK2. For example, BAY11-7082 is reported to be a
specific inhibitor of inducible IκB-alpha phosphorylation (Pierce
et al., 1997) which is in line with the finding that IκB-alpha shown
to phosphorylate LRRK2 in immune cells (Dzamko et al., 2012).
However, none of the other in vitro inactive compounds displayed
significant dephosphorylation of LRRK2 in cells. Also, it should
be noted that full dephosporylation of LRRK2 (>70–80%) was
not displayed by any of the in vitro inactive compounds and was
only observed for the most potent in vitro inhibitors of LRRK2.
Taking the overall results into account, we conclude that
LRRK2 dephosphorylation involves an important contribution of
the activity of compounds on LRRK2 itself. Therefore, the reg-
ulation of LRRK2 phosphorylation at Ser935, as well at other
sites of this phosphorylation cluster such as Ser910/955/973,
involves at least three partners, i.e., a phosphatase, a phospho-
rylating kinase as well as LRRK2 itself. We recently showed that
treatment of cells with the LRRK2 kinase inhibitor LRRK2-IN1
induced LRRK2 dephosphorylation by recruitment of protein
phosphatase 1 (PP1) (Lobbestael et al., 2013). Our findings pre-
sented here suggest that this is a more generalized phenomenon
for LRRK2 kinase inhibitors from multiple kinase classes. The
activity of these compounds may possibly require conformational
changes of the LRRK2 kinase domain to allow proper binding of
the inhibitor. Experimental evidence for this has recently been
reported, whereby detection of LRRK2 with a monoclonal anti-
body targeting the activation loop of the LRRK2 kinase domain
was altered upon binding of kinase inhibitors (Gillardon et al.,
2013). A compound induced conformational change of LRRK2
is likely to regulate binding affinities between LRRK2 and its cel-
lular interactors and is consistent with our previous observation
that PP1 is recruited to LRRK2 under conditions of dephospho-
rylation (Lobbestael et al., 2013). It remains to be determined
whether compounds can be developed which inhibit LRRK2
kinase activity but which do not induce major conformational
changes in LRRK2 leading to its dephosphorylation in cells. This
has important implications as the pS935 dephosphorylation is not
only observed after LRRK2 kinase inhibition (Deng et al., 2011;
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Choi et al., 2012; Reith et al., 2012; Zhang et al., 2012), but also in
at least some LRRK2 diseasemutants (Nichols et al., 2010; Li et al.,
2011; Lobbestael et al., 2012; Rudenko et al., 2012), therefore it is
not yet clear whether dephosphorylation is a desired effect of a
potential PD therapeutic based on LRRK2 kinase inhibition.
In conclusion, we report here the correlations between the
in vitro, cellular and in silico activities of a kinome-wide panel
of kinase inhibitors on LRRK2. Our results indicate that cel-
lular LRRK2 dephosphorylation induced by kinase inhibitors
involves a strong component of inhibitor activity on LRRK2 itself,
without excluding a role for upstream kinases. Understanding the
regulation of LRRK2 phosphorylation by kinase inhibitors has
implications for cellular activity assays of LRRK2 and may lead
to development of new classes of LRRK2 kinase inhibitors.
MATERIALS AND METHODS
IN VITRO KINASE ASSAY
LRRK2 kinase activity was assessed using an isotopic peptide
substrate assay essentially as described in reference (Taymans
et al., 2011). In short, recombinant LRRK2 was incubated with
6 μCi γ-32P-ATP [3000 Ci/mmol; Perkin Elmer (USA)], 200μM
LRRKtide (RLGRDKYKTLRQIRQ) (Jaleel et al., 2007) [Enzo
Life Sciences (USA)], 10μM ATP and kinase inhibitor (see
below) or dimethylsulfoxide (DMSO) solvent per 40μl reac-
tion in 1× kinase buffer for 30min at 30◦C. The composi-
tion of 1x kinase buffer is: Tris 25mM pH 7.5, MgCl2 10mM,
dithiothreitol (DTT) 2mM, Triton 0.02%, beta-glycerophosphate
5mM, Na3VO4 0.1mM. DMSO content of each in vitro kinase
reaction was 1 %. For the single dose testing (at 10μM of
kinase inhibitor), the LRRK2 enzyme used was GST-tagged trun-
cated LRRK2 containing residues 970 to 2527 (Life Technologies).
Reactions were stopped by the addition of 500mM EDTA
containing bromophenol blue. Reactions were spotted to P81
Whatman phosphocellulose paper (GE Healthcare) and washed
four times 10min in 75mM phosphoric acid. LRRKtide phos-
phorylation levels were measured via autoradiography (Asensio
and Garcia, 2003).
A commercially available panel of 160 kinase inhibitors
(EMD4Biosciences, Inhibitor select panel) was initially screened
at one concentration (10μM). The inhibitor panel contains
cell-permeable and previously characterized inhibitors which
together target all branches of the kinome. All inhibitors
are confirmed cell permeable, with the exception of PKCβ
Inhibitor, PKR Inhibitor—Negative Control, Alsterpaullone—2-
Cyanoethyl, Cdk1/5 Inhibitor and JNK Inhibitor IX which are
of unknown permeability. Compounds in the inhibitor panel
are mostly ATP-binding site competitive inhibitors, although
20 compounds are labeled as non ATP-competitive compounds
(including 1 allosteric compound). These compounds are: Bcr-
abl Inhibitor, AG 490, AG 112, Akt Inhibitor X, AG 1024, Akt
Inhibitor V—Triciribine, Akt Inhibitor VIII, Isozyme-Selectiv—
Akti-1/2, Chelerythrine Chloride, MEK1/2 Inhibitor, MNK1
Inhibitor, KN-62, Cdk4 Inhibitor II—NSC 625987, ERK Inhibitor
III, MK2a Inhibitor, MEK Inhibitor I, Sphingosine Kinase
Inhibitor, PD 98059, GSK-3b Inhibitor I, KN-93 and the allosteric
inhibitor IGF-1R Inhibitor II. Information on the branch of the
kinome targeted is provided together with experimental results in
Table 1; further details on each inhibitor are available from the
supplier. Then, selected molecules were further tested at lower
doses. For those selected compounds that were found to inhibit
>50% at 1μM, an IC50 (inhibitor concentration yielding 50%
inhibition) was determined. To this end, compounds were tested
in triplicate with full length LRRK2 protein (Taymans et al.,
2011; Civiero et al., 2012) at concentrations of 10μM, 1μM,
300 nM, 100 nM, 30 nM, 10 nM, 3 nM, 1 nM, 100 pM, 10 pM,
and solvent. An inhibition curve was fitted and IC50s calcu-
lated using GraphPad Prism version 5.01 forWindows (GraphPad
Software, San Diego, CA, USA). IC50s are expressed as pIC50
[= −log(IC50)].
LRRK2 CELLULAR ACTIVITY AND PHOSPHOSERINE 935 SPOTBLOT
DETECTION ASSAY
To assess LRRK2 cellular activity, an SH-SY5Y stable cell line
was first generated. SH-SY5Y cells were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 15% fetal bovine
serum and 1× non-essential amino acids (Gibco) at 37◦C and
5% CO2. Lentiviral vectors (LVs) encoding human 3xFlag-
LRRK2 under control of the cytomegalovirus (CMV) promoter
and co-expressing a hygromycin selection marker via an inter-
nal ribosomal entry site element were prepared and used for
cellular transduction as previously described (Civiero et al.,
2012). Following selection in medium containing 200μg/ml
hygromycin, cells were expanded for use in experiments.
Cells were plated out into 96-well plates. When wells were
>80% confluent, cells were treated with kinase inhibitors by
dilution of the compounds into the cell culture medium to
the desired final concentration. Following a 2 h incubation of
the cells with kinase inhibitors, cells were immediately rinsed
in PBS and lysed in lysis buffer [20mM Tris-HCl pH 7.5,
150mM NaCl, 1mM EDTA, 0.5% Tween 20 or 1% Triton X-100,
2.5mM sodium pyrophosphate, 1mM beta-glycerophosphate,
1mM NaVO4, protease inhibitor cocktail and phosphatase
inhibitor cocktail (Roche)]. Lysates were centrifuged for 30min
at 14000 × g. Supernatant was spotted to hydrated pvdf mem-
branes and LRRK2 phospho-Ser935 levels as well as total LRRK2
levels were sequentially determined by immunoblot detection
using the rabbit monoclonal anti-phospho-S935-LRRK2 anti-
body [Epitomics, clone UDD2 10(12)] and the mouse mon-
oclonal anti-LRRK2 antibody N138/6 (Neuromab) or flag-M2
antibody followed by incubation with appropriate secondary
horseradish peroxidase coupled antibodies and chemilumines-
cent detection using ECL plus HRP substrate (Thermo Scientific,
Rockford, IL, USA). Densitometric analysis of the immunore-
active spots was performed using Aida analyzer v1.0 (Raytest,
Straubenhardt, Germany). Phosphorylation levels were deter-
mined by the ratio of phospho-LRRK2 to total LRRK2, normal-
ized to solvent controls.
Z′ DETERMINATION
To determine Z′ of the in vitro LRRKtide assay or the cellular
Ser935 dephosphorylation assay, the following formula was used:
Z
′ = 1 −
(
3σ+c + 3σ−c
|μ−c − μ+c|
)
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where σ+c, σ−c, μ+c, and μ−c are the standard deviation (σ)
and mean (μ) of the positive control samples (+c, LRRK2-IN1
10μM for the LRRKtide assay, CZC 10μM treated samples in the
pS935 dephosphorylation assay) or negative control samples (−c,
DMSO treated samples). Results are based on values from 3–10
replicates from the same assay run.
MODELLING THE LRRK2 KINASE DOMAIN BASED ON MULTIPLE
TEMPLATES
All the following steps were conducted using MODELLER
9v9 (Sali and Blundell, 1993), unless otherwise stated. First,
human TKL kinases with a DFG-in activation loop confor-
mation (i.e., active conformation) available at that time in
the “Kinase Database” implemented in Molecular Operating
Environment (MOE, Chemical Computing Group Inc., 1010
Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A
2R7, 2013) were structurally aligned using the alignment.salign
command. Afterwards, this structure domain was superimposed
on the LRRK2 kinase domain. The TKL kinases B-Raf (Rapidly
accelerated fibrosarcoma) (PDB 3OG7; Bollag et al., 2010) and
MLK1 (Mixed Lineage Kinase 1) (PDB 3DTC; Hudkins et al.,
2008) and—for one short stretch of 11 amino-acids in the N-
terminal region of LRRK2 kinase (corresponding to LRRK2
amino acids 1872–1882 found just N-terminal of the P-loop, see
Figure 6A)—IRAK-4 (Interleukin-1 Receptor–Associated Kinase
4) (PDB 2NRU; Wang et al., 2006) displayed the highest identity
with the LRRK2 kinase domain and were chosen as templates.
The final alignment between B-Raf, MLK1, IRAK-4, and the
LRRK2 kinase domain is shown in Figure 6A. A 3D model of
LRRK2 kinase domain was calculated by satisfaction of spatial
restraints and screened for unfavorable regions by computing the
Discrete Optimized Protein Energy (DOPE) score per residue.
The alignment was modified using iterative alignment-modeling-
evaluation steps until no improvement could be found. For the
top-scoring alignment, multiple models were computed and sub-
jected to a rough refining procedure: each model is optimized
with the variable target function method with conjugate gradi-
ents and further refined usingmolecular dynamics with simulated
annealing. The LRRK2 kinase domain model with the best DOPE
score, GA341 score and Modeler objective function was selected.
Explicit hydrogen atoms were added and the model was sub-
jected to amore thorough refining procedure withMOE using the
AMBER99 force field with Born solvation model. First, all incon-
sistencies and outliers were selected (as observed from values
in the Ramachandran plot, backbone bond angles and lengths,
the rotamer strain energy, and atom clashes), the other residues
were potentially fixed and an energy minimization (EM) was per-
formed with backbone atoms restrained to 100. The EM was
terminated when the RMS gradient fell below 0.1. A final EM was
performed on all atoms with all backbone atoms restrained to 10.
This minimization was terminated when the RMS gradient fell
below 0.1.
QUALITY
Model quality has been checked by computational methods, giv-
ing us a good validation of the reliability of the model. The
Ramachandran Plot assured very good confidence: only 0.7%
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Table 2 | Overview of in silico, in vitro and cellular activities of selected kinase inhibitors.
Compound Compound GBVI/WSA pIC50 in vitro IC50 in vitro Cellular pS935 pIC50 cellular IC50 cellular
class dG Score (lrrktide) (lrrktide, nM) (% @ 5µM) (pS935) (pS935, nM)
AG 1478 B 0.6074 5.43 3732.50 75.11 NA NA
Aminopurvalanol A A −5.7089 5.69 2027.68 121.05 NA NA
Aurora kinase inhibitor II A 0.0905 <5 >1E4 69.85 NA NA
Bohemine A −4.9590 <5 >1E4 83.36 NA NA
BPIQ-I B −3.5711 5.12 7649.22 88.55 NA NA
Cdk1 inhibitor C −5.6508 <5 >1E4 78.35 NA NA
Cdk1 inhibitor. CGP74514A A −5.4352 5.46 3467.37 83.35 NA NA
CDK2 inhibitor III A −5.9534 <5 >1E4 100.49 NA NA
Compound 52 A −4.9190 5.41 3926.45 76.44 NA NA
Compound 56 B −2.8627 5.52 3013.01 86.56 NA NA
DMBI C −5.5592 5.83 1482.81 54.34 NA NA
EGFR/ErbB-2 inhibitor B 0.3668 <5 >1E4 67.43 NA NA
GSK-3 inhibitor IX C −3.9610 5.95 1122.02 104.53 NA NA
GSK-3 inhibitor X C −4.3149 <5 >1E4 106.06 NA NA
IC261 C −4.7642 <5 >1E4 78.81 NA NA
Indirubin derivative E804 C −6.0607 6.16 685.49 101.13 NA NA
Indirubin-3′-monoxime C −5.0838 5.75 1786.49 85.53 NA NA
JAK3 inhibitor II B 0.2193 5.92 1202.26 63.02 NA NA
JAK3 inhibitor VI C −5.6557 6.76 173.78 40.36 <5.7 >2000
Met kinase inhibitor C −4.7526 7.37 42.95 52.43 NA NA
NF-KB activation inhibitor B 0.7201 <5 >1E4 65.67 NA NA
PD 174265 B −3.4813 5.05 8871.56 67.74 NA NA
PDGF receptor tyrosine
kinase inhibitor III
B −1.7337 <5 >1E4 72.83 NA NA
PKR inhibitor C −5.8928 6.44 363.08 29 5.88 1312.00
PKR inhibitor. negative control C −5.9853 6.53 297.17 72.69 NA NA
Purvalanol A A −5.8267 5.34 4570.88 121.26 NA NA
Src kinase inhibitor I B 1.8876 6.03 936.22 61.51 NA NA
SU11652 C −7.5028 7.96 10.89 14.19 6.50 316.23
SU6656 C −7.3049 8.00 10.00 14.34 6.37 422.67
SU9516 C −5.8674 5.68 2103.78 94.62 NA NA
Syk inhibitor C −6.5548 6.20 632.41 57.29 NA NA
VEGF receptor 2 kinase
inhibitor I
C −6.6034 7.61 24.55 60.83 NA NA
VEGF receptor 2 kinase
inhibitor II
C −6.4887 7.44 36.31 37.26 <5.7 >2000
VEGF receptor 2 kinase
inhibitor III
C −5.4369 6.56 272.90 45.08 <5.7 >2000
VEGF receptor tyrosine
kinase inhibitor III. KRN63
B −0.9464 <5 >1E4 62.48 NA NA
Cdk1/2 inhibitor III NA NA 9.04 0.91 13.15 8.93 1.18
Staurosporine NA NA 9.57 0.27 8.89 8.76 1.75
LRRK2 IN1 NA NA 8.45 3.54 9.32 6.55 279.90
CZC25146 NA NA 8.75 1.78 8.62 7.36 43.65
Compounds belong to one of three different structural classes (A, 9-methyl-N-phenylpurine-2,8-diamine, B, N-phenylquinazolin-4-amine, or C, 1,3-dihydroindol-2-one
analogs, see second column) as well as selected reference compounds. In silico docking values given are GBVI/WSA dG. In vitro activities and cellular activities as
measured by the LRRKtide assay and phosphoserine 935 assay, respectively, are given both as pIC50 as well as the corresponding IC50 expressed in nM. In vitro
inhibition values at the single dose of 10 µM and cellular phosphorylation levels at 5 µM are given in Table 1 for all 160 compounds of the kinase inhibitor panel,
cellular phosphorylation levels at 5 µM are also given here for all compounds in the table. See Results and Materials and Methods sections for more details. NA,
not applicable.
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Table 3 | Overview of TKL kinases with a DFG in conformation
available in the MOE “Kinase Database” and their sequence identity
with the LRRK2 kinase domain.
PDB Family Kinase Resolution (Å) SEQ ID
3HMM STKR TGFβR1 (or ALK5) 1.70 23
3OOM ALK2 (or ActR1) 2.00 24
3MDY BMPR1B 2.05 23
3MY0 ALK1 2.65 21
3G2F BMPR2 2.35 23
2QLU ActR2 2.00 21
2NRU IRAK IRAK4 2.00 24
3OG7 RAF B-RAF 2.45 29
3OMV C-RAF (or RAF-1) 4.00 27
2EVA MLK TAK1 2.00 25
3DTC MAPKKK9 (or MLK1) 2.60 34
The PDB code, resolution and the family each kinase belongs to as well
as the sequence identity to the LRRK2 kinase domain are provided. The
three TKL kinases chosen as templates are highlighted in red. Abbreviations:
IRAK, interleukin-1 receptor–associated kinase; MLK, mixed lineage kinase; RAF,
rapidly accelerated fibrosarcoma; SEQ ID, sequence identity to the LRRK2
kinase domain; STKR, S/T kinase receptors.
residues in the disallowed region and 2.1% residues outside
generously allowed regions. 2.9% of the residues had unfavor-
able bond angles and 1.1% had unfavorable dihedrals. However,
most of these residues were oriented away from the active site
(Figure 6C). Assessment of model quality using Meta-MQAPII
(Pawlowski et al., 2008) gave absolute global deviations, expressed
as RMS deviation (3.47 Å) and Global Distance Test Total Score
(65.98), for the model vs. the unknown true structure, indicating
a medium quality model. The Meta-MQAPII score per residue
is shown in Figure 6C. The only unfavorable regions were the
loop regions, especially the activation loop, explained by the lack
of a good template for these regions (Figure 6A). Overall, the
activation loop is also rather flexible for kinases (un-crystallized
region). Since these unfavorable modeled loops are not part of
the ligand binding site, we proceeded with the LRRK2 kinase
domain homology model. PyMOL and MOE were used as a visu-
alization tool. The model is freely available upon request to the
corresponding authors.
PREPARATION OF THE IN SILICO KINASE INHIBITOR DATABASE
The kinase inhibitor database was supplied as a two-dimensional
structure data file by EMD4Biosciences (USA). Using the MOE
Structure Database Tools (sdwash, sdcharges, and sdstereo com-
mands), the database was curated. Based on the fact that
different stereoisomers may have different activities, molecu-
lar docking simulations were carried out for both stereoiso-
mers. Generation of 3D structures was done via the energy
minimize command using default settings. We used the
MMFF94x force field. All data were stored in a MOE molecular
database file.
Common substructures, based on the analysis of PDB kinase
ligands by Ghose and co-workers (Ghose et al., 2008), were found
using Instant JChem (ChemAxon, Hungary).
PROTEIN-LIGAND DOCKING AND SCORING
After homology modeling with MODELLER (Sali and Blundell,
1993), the generated alternative conformations of the ligands were
docked into the active site using MOE. A preliminary docking
step, where staurosporine was docked in the LRRK2 active site,
was applied to optimize the local environment to acquire themost
optimal binding pose in the subsequent docking step. The crystal
structures B-Raf (PDB 3OG7), MLK1 (PDB 3DTC), and IRAK-
4 (PDB 2NRU) were protonated using Protonate3D module
of MOE.
For docking simulations, initial binding conformations were
generated for the purine, quinazoline, and oxindol deriva-
tives (termed compound classes A–C) of the kinase inhibitor
database. These initial binding conformations were refined
using pharmacophore models for these three compound classes
(Figures 7A–C). The pharmacophore models were based on
structural elements, shared by all derivatives in one class that are
essential for interaction with LRRK2. During the refinement step,
ligands that fulfilled the pharmacophore hypothesis were allowed
to advance and an optimized binding conformation was saved in a
MOEmolecular database file. Ligands that didn’t satisfy the phar-
macophore requirements were excluded from subsequent steps.
The DOCKmodule was used and default settings were applied. A
force field based scoring function was used: GBVI/WSA dG. After
docking, the results were collected by receptor (i.e., docking val-
ues obtained with each of the four kinase structures tested). For
each ligand the best scoring (e.g., lowest energy) docking pose was
kept.
RECEIVER OPERATING CHARACTERISTICS PLOTS
Receiver operating characteristic plots are useful as a graphical
illustration of the performance of the in silico docking strategy
as they can evaluate the computed docking values together with
measured activities (either in vitro or cellular). Here, we plot-
ted the receiver operating characteristic plots as false positive rate
(equivalent to the 1—specificity) vs. the true positive rate (equiva-
lent to the sensitivity), therefore docking strategies which plotted
on average above the diagonal can be considered to have predic-
tive value (this is also reflected by the AUC which is >0.5 for
predictive docking strategies). In more detail, for each ligand,
the activity/inactivity was indicated by adding 1 and 0 respec-
tively based on the in vitro LRRKtide assay or cellular pS935
dephosphorylation assay. Ligands with at least 50% inhibitory
activity at 1μM in the LRRKtide assay or at least 50% inhibitory
activity at 5μM in the cellular pS935 dephosphorylation assay
were designated as active. A receiver operating characteristic plot
was generated for each receptor (i.e., for each kinase model)
using CROC v1.0 (Swamidass et al., 2010). Plots were made with
Deltagraph V7 (2014 RedRock Software, Salt Lake City, USA).
CORRELATION ANALYSIS
To evaluate the correlation between the different activities
obtained for tested kinase inhibitors, pairs of activity values were
plotted against each other in GraphPad Prism 5.01 (GraphPad
Software Inc.). Linear regression analysis was performed and a
trendline was drawn as well as the 95% confidence band. Finally,
Pearson’s r-coefficient was calculated and a two tailed correlation
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significance test performed (GraphPad). The level of statistical
significance was set at P < 0.05.
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